Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults previously vaccinated in FluAS25-003 clinical trial with the same candidate vaccine. Fluarix™ administered in young and elderly adults will be used as reference
To evaluate in elderly adults, the safety and reactogenicity of repeated vaccination with FluAS25, during 21 days following the intramuscular administration of the vaccine. Fluarix administered to you...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of GSK573719 delivered once-daily over 28 days in subjects with COPD
The primary objective of this study is to evaluate the efficacy and safety of three doses of GSK573719 (125, 250, and 500 mcg once daily) compared with placebo in subjects with COPD in order to inform...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A Phase IIIA, open, randomized study to assess immunogenicity and safety of Fluarix™/Influsplit SSW® 2010/2011 or Pandemrix™ vaccination in adults aged 18 years and above previously vaccinated with one dose of Pandemrix™
To evaluate the humoral response in terms of haemagglutination inhibition (HI) antibodies against each influenza vaccine strain corresponding to the influenza vaccine administered, at Day 21, in subje...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase III, randomised, observer-blind, multicentre study to evaluate the immunogenicity and safety of a 2-dose vaccination with the new process manufactured adjuvanted pandemic H1N1 influenza candidate vaccine in children aged 3 to 9 years old
To evaluate whether the humoral immune response of the 3.75 µg dosage with AS03A H1N1 candidate vaccine meets or exceeds the CHMP criteria at 21 days post-dose 2 vaccination. To evaluate whether the h...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in Patients with Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic Breast Cancer
To evaluate the effect of lapatinib plus capecitabine on incidence of CNS as site of first relapse as compared with trastuzumab plus capecitabine
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Study to evaluate the efficacy, safety and immunogenicity of two or three doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants
To determine if the GSK Biologicals' HRV vaccine (pooled HRV groups) given concomitantly with routine EPI vaccinations can prevent severe RV GE (>11 on the 20-point Vesikari scoring system) caused by ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development
MAJ Il y a 4 ans
A randomised, single-blind, placebo-controlled study to investigate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous infusion of GSK933776A in patients with Alzheimer’s disease
To assess the safety and tolerability of GSK933776A after single and multiple dose intravenous administration in patients with Alzheimer’s disease
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline
MAJ Il y a 4 ans
A single blind, placebo controlled, multi-centre study to investigate the pharmacokinetics, safety, tolerability and pharmacodynamics of the TRPV1 antagonist SB-705498 against the pain of acute migraine
•To assess the efficacy of SB-705498 in treating moderate-severe migraine headache
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development
MAJ Il y a 4 ans
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily compared with Placebo for 24 Weeks in Adult Subjects with Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to evaluate the efficacy, dose response, safety, tolerability and PK of three doses of losmapimod (2.5mg, 7.5mg and 15mg) administered twice daily compared with placebo ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A 2 year study to investigate belimumab in membranous nephropathy
To evaluate the efficacy of 10mg/kg belimumab for the treatment of IMN as measured by remission of proteinuria at 2 years.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant